EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

DETERMINANTES Y RESULTADOS CLÍNICOS DE LA TITULACIÓN DE LOSINHIBIDORES DEL SISTEMA RENINA-ANGIOTENSINA-ALDOSTERONA YBETABLOQUEADORES EN PACIENTES CON INSUFICIENCIA CARDIACA

Miguel Ángel Valdés Camaño, José Manuel Aguirre, Liberato González

Revista Médica de la Caja de Seguro Social · 2019

DOI: 10.64738/rmcss.41.27 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Revista Médica de la Caja de Seguro Social, 2019. Verfasst von Miguel Ángel Valdés Camaño und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction: Multiple trials have shown that renin angiotensin aldosterone system inhibitors (RAASI) (including angiotensin-converting enzyme inhibitors [ACEI] and angiotensin receptor blockers [ARB]) and beta-blockers (BB) reduce the risk of mortality and heart failure (HF) hospitalization in patients with heart failure with reduced ejection fraction (HFREF). However, in clinical practice, the proportion of patients reaching the doses studied in these trials is small. Methods: through a prospective study, we identified patients with HFREF, admitted to Heart Failure Clinic of Dr. Arnulfo Arias Madrid Hospital Complex between February and August 2017, and were followed until November 2018. High doses were defined as equal to or greater than 50% and low doses as less than 50%, both ISRAA and BB Results: we identified 54 patients; 35.8% reached high doses of RAASI and 37.7% achieved high doses of BB. HF hospitalization rate in high-dose versus low-dose RAASI group was 0% versus 25% (p: 0.024), and 0% vs. 27.3% in high-dose versus low-dose beta-blocker group (p: 0.010) Conclusions: use of high doses of RAASI and BB reduces the risk of HF hospitalization in patients with HFREF, compared with low doses.

Zitieren

APA

Camaño, M. Á. V., Aguirre, J. M., & González, L. (2019). DETERMINANTES Y RESULTADOS CLÍNICOS DE LA TITULACIÓN DE LOSINHIBIDORES DEL SISTEMA RENINA-ANGIOTENSINA-ALDOSTERONA YBETABLOQUEADORES EN PACIENTES CON INSUFICIENCIA CARDIACA. Revista Médica de la Caja de Seguro Social. https://doi.org/10.64738/rmcss.41.27

Vancouver

Camaño MÁV, Aguirre JM, González L. DETERMINANTES Y RESULTADOS CLÍNICOS DE LA TITULACIÓN DE LOSINHIBIDORES DEL SISTEMA RENINA-ANGIOTENSINA-ALDOSTERONA YBETABLOQUEADORES EN PACIENTES CON INSUFICIENCIA CARDIACA. Revista Médica de la Caja de Seguro Social. 2019. doi:10.64738/rmcss.41.27

BibTeX
@article{Camao2019,
  author = {Camaño, Miguel Ángel Valdés and Aguirre, José Manuel and González, Liberato},
  title = {DETERMINANTES Y RESULTADOS CLÍNICOS DE LA TITULACIÓN DE LOSINHIBIDORES DEL SISTEMA RENINA-ANGIOTENSINA-ALDOSTERONA YBETABLOQUEADORES EN PACIENTES CON INSUFICIENCIA CARDIACA},
  journal = {Revista Médica de la Caja de Seguro Social},
  year = {2019},
  doi = {10.64738/rmcss.41.27}
}
Kostenlos starten →